This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agilent (A) Sues Former Employees for Infringing IP Rights
by Zacks Equity Research
Agilent Technologies has sued its former employees who formed Shanghai Echrom Electronic Technology Co.
Why Is Abbott Laboratories (ABT) Down 3.1% Since the Last Earnings Report?
by Zacks Equity Research
Abbott Laboratories (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott-North West London Pathology Expand in Diagnostics
by Zacks Equity Research
Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
Profit from the Dollar's Dip with These 5 S&P 500 Stocks
by Swarup Gupta
Companies with significant overseas exposure stand to gain from the dollar's dip.
Company News for July 21, 2017
by Zacks Equity Research
Companies In The News are: ABT,KMI,PM,TRV
Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up
by Zacks Equity Research
Abbott Labs' (ABT) Q2 performance was strong on solid EPD and Medical Device growth. The stock's guidance for 2017 has also been raised.
Abbott (ABT) Tops Earnings Estimates in Q2, Misses on Sales
by Zacks Equity Research
Abbott Laboratories (ABT) gains on strong Q2 performance. Raised guidance buoys optimism.
The Hottest Earnings Charts of the Week
by Tracey Ryniec
It's not easy to beat on earnings nearly every quarter but these 5 companies are doing it.
Medical Product Stocks' Earnings on Jul 20: ABT, ISRG & More
by Zacks Equity Research
The market remained jittery towards medical space due to uncertainties surrounding the future of the healthcare act.
Can Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report second-quarter 2017 results before the opening bell on Jul 20.
Abbott Partners Bigfoot Biomedical to Expand in Diabetics
by Zacks Equity Research
Illinois-based global medical device company Abbott Laboratories (ABT) partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market.
Edwards Emerges Strong on FDA Nods, International Prospect
by Zacks Equity Research
On Jul 11, we issued an updated research report on the leading molecular diagnostic company, Edwards Lifesciences Corporation (EW).
LabCorp Diagnostics Strong on Novant Health Deal Extension
by Zacks Equity Research
Laboratory Corporation of America Holdings (LH), also referred to as LabCorp, has decided to extend its Technical Services Agreement with Novant Health which was originated in 2012.
Medtronic (MDT) Launches Resolute Onyx DES Device in Japan
by Zacks Equity Research
Medtronic plc (MDT), a leading global player in medical technology, services and solutions, is set to make another encouraging move with respect to its highest revenue grossing Cardiovascular segment.
Thermo Fisher at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Thermo Fisher Scientific Inc. (TMO), headquartered in Waltham, MA, scaled a new 52-week high of $177.99 on Jul 7, eventually closing a shade lower at $177.49.
Investors Look for Gains as Abbott Labs Set to Acquire Alere
by Zacks Equity Research
On majority of Alere shareholders' recent approval in favor of the merger with Abbott (ABT), the deal is now expected to close by the end of third-quarter 2017.
Phibro Animal Health & Zydus Cadila Plan to Expand in India
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC) recently announced plans to enter into a long-term agreement with global pharmaceutical company Zydus Cadila to expand in the rapidly growing poultry market in India.
Exactech Boosts Knee System Portfolio, Launches New App
by Zacks Equity Research
Exactech, Inc.(EXAC) took a step towards it's goal of providing an all-inclusive range of knee replacement systems with the launch of ExactechGPS TKA PLUS.
Here's Why You Should Add Abbott Laboratories Right Now
by Zacks Equity Research
Illinois-based global medical device company Abbott Laboratories (ABT) has been gaining investor confidence on consistent positive results
Abbott Freestyle Libre System Gets Health Canada License
by Zacks Equity Research
Abbott Laboratories (ABT) recently announced the receipt of Health Canada license for its FreeStyle Libre Flash Glucose Monitoring System.
5 Underfollowed Stocks That Are Projected To Explode
by Jeffrey Hymen
These stocks represent a few investments that could possibly turn out to be hidden gems.
2 Solid Medical Device Stocks to Scoop Up Right Away
by Zacks Equity Research
Let's focus on two medical device stocks which will make valuable additions to an investment portfolio in the wake of widespread volatility in the medical device market.
The Zacks Analyst Blog Highlights: United Technologies, Abbott, Delta Air, Equity Residential and Ross Stores
by Zacks Equity Research
The Zacks Analyst Blog Highlights: United Technologies, Abbott, Delta Air, Equity Residential and Ross Stores
Abbott Laboratories Up on EPD & Buyouts, Pediatric Weak
by Zacks Equity Research
On Jun 14, we issued an updated research report on Illinois-based Abbott Laboratories (ABT). It is a leading distributor of health care products and services across the globe.